Results 211 to 220 of about 323,413 (255)

Pharmacokinetics of prostaglandins

Best Practice & Research Clinical Obstetrics & Gynaecology, 2003
Naturally occurring prostaglandins (PGs) are rapidly metabolized in the human circulation. For clinical use a number of PG analogues have therefore been developed which are resistant to rapid inactivation. Among these are carboprost, gemeprost and misoprostol.
openaire   +2 more sources

Psychopharmacology and pharmacokinetics

2019
The overall physiologic changes associated with aging lead to changes in both pharmacokinetic and pharmacodynamic actions of many medications. This, in turn, leads to changes in the impact that a wide variety of medications have on older adults when compared to younger, healthy individuals. These pharmacokinetic and pharmacodynamic variations can cause
Jacob, Tillmann, Ashley, Reich
openaire   +2 more sources

Lamotrigine: Pharmacokinetics

Journal of Child Neurology, 1997
The pharmacokinetics of lamotrigine have been studied in single and multiple dose studies in animals, normal volunteers, and patients with epilepsy. Lamotrigine exhibits first-order linear pharmacokinetics. Lamotrigine is well absorbed with bioavailability approaching 100%. The absorption is unaffected by food and there is no first-pass metabolism. The
openaire   +2 more sources

Pharmacokinetics of Peginterferons

Seminars in Liver Disease, 2003
Two polyethylene glycol (PEG)-modified interferons are approved for the treatment of chronic hepatitis C. The pharmocokinetic properties of the branched 40 kDa pegylated interferon alfa-2a differ from the linear 12 kDa pegylated interferon alfa-2b.
Stefan, Zeuzem, Christoph, Welsch, Eva, Herrmann   +2 more
openaire   +2 more sources

Pharmacokinetics of desogestrel

American Journal of Obstetrics and Gynecology, 1993
A synthetic form of desogestrel, a gonane progestin, was developed because desogestrel's enhanced selectivity eliminates adverse, androgen-dependent, metabolic effects at contraceptive doses. Desogestrel is rapidly and completely metabolized in the liver and gut wall to 3-keto-desogestrel, which is the active metabolite mediating the progestin effects.
H D, McClamrock, E Y, Adashi
openaire   +2 more sources

Pharmacokinetics of lisinopril

The American Journal of Medicine, 1988
The angiotensin-converting enzyme inhibitor, lisinopril, has an oral bioavailability of 25 percent +/- 4 percent, which is unaffected by food. The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours. Steady state is attained after two daily doses (every 24 hours) in healthy volunteers. The drug is not
openaire   +2 more sources

Developmental Pharmacokinetics

Seminars in Pediatric Neurology, 2010
Physiological differences between children and adults result in age-related differences in pharmacokinetics and drug effect. In neonates and infants, decreased weight-adjusted doses are required because of decreased protein binding, renal excretion, and/or metabolism.
openaire   +2 more sources

Pharmacokinetics of vancomycin

Journal of Antimicrobial Chemotherapy, 1984
Vancomycin is poorly absorbed when administered by mouth and, for systemic infections, must be given intravenously. The pharmacokinetics of vancomycin have been well defined in a number of recent studies in man. Since the drug is excreted primarily via the kidneys, dosage modification is imperative in patients with impaired renal function.
openaire   +2 more sources

Quinolone pharmacokinetics

International Journal of Antimicrobial Agents, 1992
Fluoroquinolones have broad antibacterial spectra and are active against most Gram-negative and many Gram-positive species. They exhibit excellent oral bioavailability, extensive tissue penetration, low protein binding, and a long elimination half-life.
openaire   +2 more sources

Pharmacokinetics of endralazine

European Journal of Clinical Pharmacology, 1984
H L, Elliott, P A, Meredith, J L, Reid
openaire   +2 more sources